| The genetics and screening of familial hypercholesterolaemia R Henderson, M O’Kane, V McGilligan, S Watterson Journal of biomedical science 23, 1-12, 2016 | 176 | 2016 |
| The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study RH Henderson, D French, T Maughan, R Adams, C Allemani, P Minicozzi, ... The lancet Gastroenterology & hepatology 6 (9), 709-722, 2021 | 57 | 2021 |
| Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems N Normanno, K Apostolidis, F de Lorenzo, PA Beer, R Henderson, ... Seminars in cancer biology 84, 293-301, 2022 | 35 | 2022 |
| Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses R Henderson, D French, R Sullivan, T Maughan, M Clarke, M Lawler Oncotarget 10 (36), 3408-3423, 2019 | 17 | 2019 |
| Opportunities and barriers to the development and use of open source health economic models: a survey XGLV Pouwels, CJ Sampson, RJG Arnold, MD Janodia, R Henderson, ... Value in health 25 (4), 473-479, 2022 | 16 | 2022 |
| Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: A systematic review R Henderson, P Keeling, D French, D Smart, R Sullivan, M Lawler Molecular oncology 15 (10), 2672-2687, 2021 | 12 | 2021 |
| Shooting for the moon or flying too near the sun? Crossing the value Rubicon in precision cancer care M Lawler, D French, R Henderson, A Aggarwal, R Sullivan Public Health Genomics 19 (3), 132-136, 2016 | 9 | 2016 |
| Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach RH Henderson, D French, E Stewart, D Smart, A Idica, S Redmond, ... Journal of Pharmaceutical Policy and Practice 16 (1), 84, 2023 | 7 | 2023 |
| Spend less to achieve more: economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer RH Henderson, D French, E McFerran, R Adams, H Wasan, ... Journal of Cancer Policy 33, 100342, 2022 | 3 | 2022 |
| COST-EFFECTIVENESS OF PRECISION DIAGNOSTIC TESTING AND PRECISION MEDICINE FOR NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW R Henderson, M Lawler, P Keeling, D French, D Smart, S Finucane, ... VALUE IN HEALTH 23, S33-S33, 2020 | 2 | 2020 |
| Precision versus non-precision oncology drug submissions to the National Centre for Pharmacoeconomics in Ireland R Henderson, T Bhatnagar, K Patterson, M Kaur, S Redmond ISPOR Europe 25 (12), S334, 2022 | 1* | 2022 |
| Economic burden of not testing for FLT3 to treat acute myeloid leukemia. R Henderson, D Smart, D French, J Clark, KJ Bloom, D Hosty, M Lawler Journal of Clinical Oncology 38 (15_suppl), e13652-e13652, 2020 | 1 | 2020 |
| Landscape Review and Economic Potential of the Oncology and Allied Digital Health Sector on the Island of Ireland R Henderson, N O'Flatharta, K Patterson, S Redmond https://zenodo.org/records/11073410, 2024 | | 2024 |
| HTA86 Factors Affecting Time to Reimbursement of Novel Anticancer Drugs in Ireland R Henderson, S Redmond Value in Health 26 (12), S335, 2023 | | 2023 |
| Association of NCPE Submission Outcomes in Ireland with Additional Benefit Rating in Germany T Bhatnagar, R Henderson, S Redmond ISPOR Europe 25 (12), S323, 2022 | | 2022 |
| Association of NCPE Submission Outcomes in Ireland with Added Therapeutic Value (ASMR) Rating in France M Kaur, T Bhatnagar, R Henderson, S Redmond ISPOR Europe 25 (12), S315, 2022 | | 2022 |
| Abstract P5-14-04: Changes in management of TNBC during the COVID19 pandemic of 2020 D Smart, WL Allen, RH Henderson, S Munksted, P Riccelli Cancer Research 82 (4_Supplement), P5-14-04-P5-14-04, 2022 | | 2022 |
| Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020 D Smart, W Moore, K Hjort, K Keating, B Holt, R Henderson, P Riccelli, ... Blood 138, 5017, 2021 | | 2021 |
| PPM2 The Potential Healthcare and Economic Impact of the Implementation of the in Vitro Diagnostic Regulation on Non-Small-Cell Lung Cancer Patients in the European Union R Henderson, D Smart, D French, M Lawler Value in Health 24, S195, 2021 | | 2021 |
| Does the precision oncology medicine development pathway deliver value for health systems? R Henderson, D French, E Stewart, D Smart, A Idica, J Clark, M Eckstein, ... Journal of Clinical Oncology 39 (15_suppl), e18818-e18818, 2021 | | 2021 |
Prof Richard SullivanKings Health PartnersVerified email at doctors.org.uk
